FIGURE

Fig. 6

ID

ZDB-FIG-181206-20

Publication

Xu et al., 2018 - Inhibition of TBK1/IKKε Promotes Regeneration of Pancreatic β-cells

Other Figures

All Figure Page

Back to All Figure Page

Fig. 6

Suppression of the TBK1/IKKε-PDE3 signaling axis promotes β-cell proliferation by increasing cAMP levels and mTOR activity. (A) Schematic of the TBK1/IKKε-PDE3 signaling that modulates cAMP-PKA-mTOR pathway. The sites of inhibition by PIAA and cilostamide are shown in red. (B) Quantification of cAMP levels (mean ± SD) at 48 hpa (0.4 ± 0.1 pmol/larva (DMSO) and 0.9 ± 0.0 pmol/larva (PIAA)). (C) Representative Western blot showing increased pS6K1 levels in PIAA-treated recovering larvae. (D-I’) Confocal images of [Tg(ins:CFP-NTR)^s892; Tg(ins:Kaede)^jh6] larvae at 48 hpa, concurrently treated with EdU and DMSO (D-D’), PIAA (E-E’), cilostamide (F-F’), a combination of PIAA and cilostamide (G-G’), a combination of PIAA and rapamycin (H-H’), or a combination of cilostamide and rapamycin (I-I’), respectively, from 0–48 hpa, stained for pRPS6 (blue). The number of EdU-incorporated (white arrows) and pRPS6-positive (white arrowheads) β-cells was increased in recovering larvae treated with both PIAA and cilostamide (G,G’) compared to individual compound-treated larvae (E-E’ and F-F’). Rapamycin substantially suppressed the PIAA- and cilostamide-dependent increases in the number of EdU-incorporated and pRPS6-positive β-cells (H-I’). (J) Quantification of the number (mean ± SD) of total regenerated β-cells (green bars) and regenerated β-cells that incorporated EdU with pRPS6 immunoreactivity (white bars) at 48 hpa (in D-I’; 5.0 ± 1.3 total regenerated β-cells, of which 0.3 ± 0.5 (DMSO), 17.8 ± 2.8, of which 8.4 ± 1.7 (PIAA), 12.7 ± 1.9, of which 5.0 ± 1.5 (cilostamide), 24.7 ± 1.2, of which 13.3 ± 0.6 (PIAA and cilostamide), 6.0 ± 2.0, of which 1.0 ± 1.0 (PIAA and rapamycin), and 5.2 ± 1.1, of which 0.8 ± 0.8 (cilostamide and rapamycin) incorporated EdU with pRPS6 immunoreactivity). (K) The percentage (mean ± SD) of regenerated β-cells that incorporated EdU with pRPS6 immunoreactivity at 48 hpa (in D-I’; 6.1 ± 9.5% (DMSO), 47.3 ± 7.5% (PIAA), 50.4 ± 8.8% (cilostamide), 54.2 ± 4.2% (PIAA and cilostamide), 13.9 ± 12.7% (PIAA and rapamycin), and 13.7 ± 13.0% (cilostamide and rapamycin)). Cells in 20 planes of confocal images from 10 individual larvae were counted per condition. ***P < 0.001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci. Rep.